Previous 10 | Next 10 |
Theravance Biopharma, Inc. (TBPH) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Gail Cohen – Vice President-Corporate Communications Rick Winningham – Chairman and Chief Executive Officer Rhonda Farnum – Senior Vice President and Chief Busin...
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Theravance Biopharma, Inc. 2022 Q1 - Results - Earnings Call Presentation
Theravance Biopharma press release (NASDAQ:TBPH): Q1 GAAP EPS of -$0.34 misses by $0.23. Revenue of $13.2M (-7.4% Y/Y) misses by $1.28M. For further details see: Theravance Biopharma GAAP EPS of -$0.34 misses by $0.23, revenue of $13.2M misses by $1.28M
Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update PR Newswire Implied 35% share of YUPELRI ® (revefenacin) net sales 1 : $15.3M Q1 2022 up 19% from Q1 2021 TRELEGY Q1 2022 global ...
Theravance Biopharma (NASDAQ:TBPH) is scheduled to announce Q1 earnings results on Thursday, May 5th, after market close. The consensus EPS Estimate is $0.10 (+108.1% Y/Y) and the consensus Revenue Estimate is $14.48M (+1.5% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revis...
Theravance Biopharma to Report First Quarter 2022 Financial Results on May 5, 2022 PR Newswire DUBLIN , May 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2022 financial results and provide a business ...
Commercial-stage pharma company, Theravance Biopharma (NASDAQ:TBPH) has lost ~5% in the post-market Monday after announcing that its second Phase 3 trial for ampreloxetine in symptomatic neurogenic orthostatic hypotension ((nOH)) did not achieve statistical significance for main goa...
Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH) PR Newswire Results from Study 0170 show a benefit in study patients with multiple system atro...
Theravance failed 3 trials last year. There was a major restructuring and change of focus. A small revenue stream from YUPELRI is its only positive, but that doesn't justify the valuation. For further details see: Theravance: All-Round Failure
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Theravance Biopharma, Inc. 2021 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...